Comparable stake leader
Fairmount Funds Management LLC
SEC ownership of Damora Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001800315.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- DMRA on Nasdaq
- Parsed ownership sources
- 13F, 13D/G, and 3/4/5
- Largest SEC-reported holder
- Fairmount Funds Management LLC
- Latest 13D/G holder
- Fairmount Funds Management LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001800315
- Issuer location
- Waltham, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Damora Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 20%
13D/G row: Fairmount Funds Management LLC
Showing 1-8 of 50 holder rows.
Quick read
Fairmount Funds Management LLC leads the comparable SEC ownership view at 20%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership
Top 5
Fairmount Funds Management LLC
20%
FMR LLC
15%
Avoro Capital Advisors LLC
6.3%
Venrock Healthcare Capital Partne...
6%
Paragon Therapeutics, Inc.
3.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC |
13F
13D/G
3/4/5
Company · Director, 10%+ Owner
|
20%
from 13D/G
|
$225,666,700
8,713,000 shares
|
— | 31 Mar 2026 |
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$234,277,957
9,045,481 shares
|
— | 31 Mar 2026 |
| Avoro Capital Advisors LLC |
13F
13D/G
Company
|
6.3%
from 13D/G
|
$97,979,700
3,783,000 shares
|
— | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
6%
|
$78,630,443
3,603,595 shares
|
$0 | 09 Feb 2026 |
| Paragon Therapeutics, Inc. |
13D/G
|
3.4%
|
—
2,045,473 shares
|
$0 | 09 Feb 2026 |
| Paramora Holding LLC |
13D/G
|
3.4%
|
—
2,045,473 shares
|
$0 | 09 Feb 2026 |
| Point72 Asset Management, L.P. |
13F
13D/G
Company
|
2%
from 13D/G
|
$30,917,037
1,193,708 shares
|
— | 31 Mar 2026 |
| Ikarian Capital, LLC |
13F
13D/G
Company
|
0.6%
from 13D/G
|
$8,694,889
335,710 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$27,172.
Buys
$0
Insiders: 0
Sells
$27,172
Insiders: 3
Net
-$27,172
Shares: -2,232
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 2,232
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 1,090 | $0 | $23,308 | -$23,308 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 1,142 | $0 | $3,864 | -$3,864 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 29 reporting-owner rows connected to Damora Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
29
Largest Forms 3/4/5 holder
Fairmount Funds Management LLC
Net 12M change
-$27,172
Latest report
01 May 2026
Recent insider transactions for Damora Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jennifer Jarrett | DMRA | Common Stock | Award | 500,000 | 500,000 | 30 Mar 2026 | Direct | |||
| Jennifer Jarrett | DMRA | Stock Option (right to buy) | Award | 1,500,000 | 1,500,000 | 30 Mar 2026 | Direct | |||
| Garrett Winslow | DMRA | Stock Option (right to buy) | Award | 250,000 | 250,000 | 23 Mar 2026 | Direct | |||
| Cameron Turtle | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | Direct | |||
| Michael Landsittel | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | Direct | |||
| Fairmount Funds Management LLC | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | By: Peter Harwin | |||
| Fairmount Funds Management LLC | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | By: Peter Harwin | |||
| Fairmount Funds Management LLC | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | By: Peter Harwin | |||
| Fairmount Funds Management LLC | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | By: Peter Harwin | |||
| Fairmount Funds Management LLC | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | By: Peter Harwin | |||
| Christopher W. Cain | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | Direct | |||
| Julianne Bruno | DMRA | Stock Option (right to buy) | Award | 37,313 | 37,313 | 23 Mar 2026 | Direct | |||
| Julianne Bruno | GLTO | Common Stock | Options Exercise | 1606.1% | 129,000 | 137,032 | 09 Feb 2026 | Direct | ||
| Julianne Bruno | GLTO | Series C Preferred Stock | Options Exercise | -100% | -129 | 0 | 09 Feb 2026 | Direct | ||
| Fairmount Funds Management LLC | GLTO | Common Stock | Options Exercise | 2,904,000 | 2,904,000 | 09 Feb 2026 | By Fairmount Healthcare Co-Invest V L.P. | |||
| Fairmount Funds Management LLC | GLTO | Common Stock | Options Exercise | 5,809,000 | 5,809,000 | 09 Feb 2026 | By Fairmount Healthcare Fund II L.P. | |||
| Fairmount Funds Management LLC | GLTO | Series C Preferred Stock | Options Exercise | -83.5% | -2,904 | 574 | 09 Feb 2026 | By Fairmount Healthcare Co-Invest V L.P. | ||
| Fairmount Funds Management LLC | GLTO | Series C Preferred Stock | Options Exercise | -83.5% | -5,809 | 1,148 | 09 Feb 2026 | By Fairmount Healthcare Fund II L.P. | ||
| Sherwin Sattarzadeh | GLTO | Common Stock | Award | 190,376 | 190,376 | 05 Jan 2026 | Direct | |||
| Sherwin Sattarzadeh | GLTO | Stock Option (right to buy) | Award | 444,209 | 444,209 | 05 Jan 2026 | Direct | |||
| L. Becker Hewes | GLTO | Common Stock | Award | 264,629 | 264,629 | 05 Jan 2026 | Direct | |||
| L. Becker Hewes | GLTO | Stock Option (right to buy) | Award | 528,603 | 528,603 | 05 Jan 2026 | Direct | |||
| Schambye Hans T. | GLTO | Common Stock | Sale | -13% | $14,966 | $21.38 | -700 | 4,682 | 02 Jan 2026 | Direct |
| Schambye Hans T. | GLTO | Common Stock | Options Exercise | 33.8% | 1,360 | 5,382 | 02 Jan 2026 | Direct | ||
| Schambye Hans T. | GLTO | Restricted Stock Units | Options Exercise | -34% | -1,360 | 2,640 | 02 Jan 2026 | Direct | ||
| Garrett Winslow | GLTO | Common Stock | Sale | -12.1% | $5,452 | $21.38 | -255 | 1,854 | 02 Jan 2026 | Direct |
| Garrett Winslow | GLTO | Common Stock | Options Exercise | 47.6% | 680 | 2,109 | 02 Jan 2026 | Direct | ||
| Garrett Winslow | GLTO | Restricted Stock Units | Options Exercise | -34% | -680 | 1,320 | 02 Jan 2026 | Direct | ||
| Lori Firmani | GLTO | Common Stock | Sale | -12.7% | $2,890 | $21.41 | -135 | 931 | 02 Jan 2026 | Direct |
| Lori Firmani | GLTO | Common Stock | Options Exercise | 54% | 374 | 1,066 | 02 Jan 2026 | Direct | ||
| Lori Firmani | GLTO | Restricted Stock Units | Options Exercise | -34% | -374 | 726 | 02 Jan 2026 | Direct | ||
| Schambye Hans T. | GLTO | Common Stock | Sale | -15.4% | $2,484 | $3.38 | -735 | 4,022 | 03 Jul 2025 | Direct |
| Schambye Hans T. | GLTO | Common Stock | Options Exercise | 40% | 1,360 | 4,757 | 03 Jul 2025 | Direct | ||
| Schambye Hans T. | GLTO | Restricted Stock Units | Options Exercise | -25.4% | -1,360 | 4,000 | 03 Jul 2025 | Direct | ||
| Garrett Winslow | GLTO | Common Stock | Sale | -15.4% | $881 | $3.39 | -260 | 1,429 | 03 Jul 2025 | Direct |
| Garrett Winslow | GLTO | Common Stock | Options Exercise | 67.4% | 680 | 1,689 | 03 Jul 2025 | Direct | ||
| Garrett Winslow | GLTO | Restricted Stock Units | Options Exercise | -25.4% | -680 | 2,000 | 03 Jul 2025 | Direct | ||
| Lori Firmani | GLTO | Common Stock | Sale | -17.5% | $498 | $3.39 | -147 | 692 | 03 Jul 2025 | Direct |
| Lori Firmani | GLTO | Common Stock | Options Exercise | 80.4% | 374 | 839 | 03 Jul 2025 | Direct | ||
| Lori Firmani | GLTO | Restricted Stock Units | Options Exercise | -25.4% | -374 | 1,100 | 03 Jul 2025 | Direct | ||
| Jayson Donald Alexander Dallas | GLTO | Stock Option (right to buy) | Award | 720 | 720 | 18 Jun 2025 | Direct | |||
| Amit Munshi | GLTO | Stock Option (right to buy) | Award | 720 | 720 | 18 Jun 2025 | Direct | |||
| David Shapiro | GLTO | Stock Option (right to buy) | Award | 720 | 720 | 18 Jun 2025 | Direct | |||
| Anne Prener | GLTO | Stock Option (right to buy) | Award | 720 | 720 | 18 Jun 2025 | Direct | |||
| Amy B. Wechsler | GLTO | Stock Option (right to buy) | Award | 720 | 720 | 18 Jun 2025 | Direct | |||
| Carl Goldfischer | GLTO | Stock Option (right to buy) | Award | 1,440 | 1,440 | 18 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.